Latest Advances in Lung Cancer Research

A new NYT report shows that only a small fraction of people who qualify for lung-cancer screening get tested, leaving many early cancers undetected.

A Forbes article warns that few eligible Americans get lung cancer screening the and cancellation of a USPSTF meeting could delay important updates, worsening underuse.

A new Phase 3 trial finds Ivonescimab paired with chemotherapy delayed lung cancer progression by 40 % compared to a PD-1 inhibitor combo.

A new study finds that people who worked at the World Trade Center (WTC) after 9/11 and had heavy dust exposure were nearly three times more likely to develop lung cancer.

French study finds chemotherapy after lung cancer surgery shows unclear benefits for patients over 75, requiring careful patient selection.

Tarlatamab extends survival and reduces side effects for small cell lung cancer patients, emerging as a promising new second-line treatment option.

Researchers used multi-omics (genetic, protein-related) data to find new molecular weaknesses in non-small cell lung cancer and offering fresh avenues for therapies.

A 65-year-old surfer overcame early-stage EGFR-positive lung cancer using stereotactic body radiation therapy (SBRT), a precise, non-surgical treatment that spared his lung capacity.

The FDA has approved a new drug called Datroway (datopotamab deruxtecan) for patients with EGFR-positive non-small cell lung cancer (NSCLC) who have already tried targeted therapy and chemotherapy. This approval marks an important step forward in lung cancer treatment.

A new study provides the first genetic evidence that air pollution causes DNA mutations leading to lung cancer in people who have never smoked, helping explain why lung cancer rates are rising among never-smokers worldwide, particularly women and those of Asian ancestry.

Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.

Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.